Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.

The L457(3.43)R mutation in the human lutropin receptor causes increased activity and hormone insensitivity, leading to precocious puberty.

CAH is a genetic disorder affecting cortisol production and causing hormonal imbalances, with treatment and diagnosis varying by form and symptoms.

Wigs significantly improve the well-being of people with severe hair loss.

Some people with severe, long-lasting baldness responded well to a specific combination treatment.

Hair absorbs different substances from solutions based on pH levels.

Different conditions affect how hair proteins assemble, and certain mutations can change their structure.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Trichoscopy is useful for diagnosing and monitoring alopecia areata treatment.

Low vitamin D levels are common in people with Alopecia Areata.

This therapy effectively treats resistant alopecia areata with minimal side effects.

Balneophototherapy effectively treats ichthyosis linearis circumflexa but may need ongoing treatment due to short remission.

Hair absorbs alkali bromide salts and water, affecting its structure, with absorption decreasing at higher temperatures.

COVID-19 doesn't make alopecia areata worse.

Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.

Oral tofacitinib is a promising treatment for beard hair loss in alopecia areata.

Stopping JAK inhibitor treatment for hair loss can lead to worse hair loss than before the treatment.

Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Tofacitinib is effective and safe for treating severe hair loss in a Saudi population.

The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.

Both topical calcipotriol and narrowband UVB improved alopecia, but combining them didn't enhance the effect on hair loss severity, despite higher vitamin D3 levels.

Combining calcipotriol with mometasone is more effective for treating alopecia areata than using mometasone alone.

Baricitinib helps regrow hair in adults with severe alopecia better than a placebo and is approved for treatment, but long-term effects are still unknown.

Wharton's jelly-derived stem cells were safely used to treat four alopecia patients, resulting in hair regrowth in all of them.

Japanese patients with alopecia areata often have a higher BMI and consume more vitamin C, fruit, and retinol, which may affect their condition's development or severity.

People with Alopecia areata often have lower vitamin D levels, which may be linked to the severity of their condition.

An 8-year-old with severe hair loss regrew all hair after six months of tofacitinib treatment.

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.